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Abstract 
 Olomoucine and Roscovitine are two ATP-competing compounds described as 
specific inhibitors of cyclin-dependent kinases (CDK). Both drugs showed to induce 
apoptosis in SH-SY5Y, a neuroblastoma-derived cell line. In these cells, neither Bcl-2 
nor Bcl-XL overexpression conferred any resistance to both drugs. However, a partial 
protective effect was detected when cells were treated with a general inhibitor of 
caspases (zVADfmk), cycloheximide (CHX) or actinomycin D (DAct). Interestingly, a 
synergism in cell protection was observed between zVADfmk and the macromolecular 
synthesis inhibitors, thus suggesting different apoptotic pathways in distinct 
subpopulations of the cell culture. On the other hand, no lethality was found when cells 
were treated with either PD98059 or UO126. This discarded Erk1/Erk2 inhibition as the 
cause of apoptosis. Furthermore, SH-SY5Y cells became resistant to either Olomoucine 
or Roscovitine upon the induction of differentiation. This resistance correlated with the 
extent of differentiation and, therefore, the number of cells entering a quiescent state. In 
conclusion, our results seem to support a role for CDK inhibition as the cause of the 
apoptotic process triggered by Olomoucine and Roscovitine. In addition, we contribute to 
define a promising profile as anticancer drugs for both compounds, at least in the 
treatment of neuroblastoma. 
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Introduction 
Protein kinases are pivotal elements in the regulation of cellular functions. The 
human genome is estimated to contain 518 protein kinases grouped in 7 major 
evolutionarily defined families [1]. Most human pathologies are the result of cellular 
dysfunction. Protein kinases are involved in either the genesis or the modulation of most 
of these dysfunctions. As a consequence, protein kinases become an obvious target for 
the design of new drugs. Cyclin-dependent kinases (CDK) are a family of protein kinases 
involved in the ordered succession of the cell cycle phases. CDK are controlled by 
several independent mechanisms such as the binding of positive and negative 
regulatory proteins, the state of phosphorylation and the location inside the cell [2]. Their 
pharmacological modulation is approached with increasing interest by the drug industry. 
Based on an ATP competing mode of action, several drugs are presently available to 
inhibit CDK. These drugs display a variable degree of specificity [3-5]. Staurosporine 
(STS), for instance, is an unspecific inhibitor of protein kinases with a spectrum that 
includes CDK. Other compounds, like UCN-01 or Flavopiridol, have reached clinical 
phases of development as anticancer drugs. Flavopiridol is the best example of a first 
generation of inhibitors, specific for CDK but with a low discriminating power among CDK 
subtypes. A second generation of compounds with increased specificity towards a 
precise set of CDK has been also synthesized. Olomoucine and Roscovitine belong to 
this second generation and show "in vitro" specificity for CDK1, CDK2 and CDK5 [6,7].  
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Neoplasia is characterized by an uncontrolled cell proliferation. In this context, the 
pharmacological inhibition of CDK implies the stop of the cell cycle and a brake to cell 
proliferation [8]. This can be defined as a cytostatic effect. In addition, CDK inhibitory 
drugs could induce cell differentiation. STS, for instance, stimulates cell differentiation of 
neuroblastoma [9]. Cell differentiation is a mechanism that opposes to cancer 
development. Therefore, a differentiation effect must be considered in these drugs. 
Finally, these drugs are effective in triggering apoptosis [4,8]. As a consequence, a 
cytocidal effect completes a promising profile as anticancer agents. Surprisingly, there 
are few studies approaching the cell and molecular mechanisms involved in the 
induction of apoptosis by this type of drugs. 
Apoptosis is a specific type of cell death. Apoptosis was initially defined on a 
morphological basis, in brief cell shrinking and fragmentation, chromatin condensation 
and phagocytosis by neighboring or specialized cells. Apoptosis is an ordered process, 
an orchestrated succession of cell and molecular events shared by most experimental 
paradigms of the phenomenon. In the process we can distinguish three phases named 
induction, execution and resolution. The resolution phase is the latest one and 
comprises the cell fragmentation and phagocytosis phenomena. The execution phase is 
defined by caspase activation [10,11]. Caspases are a family of proteases characterized 
by having a cysteine in their catalytic center and cleaving proteins at aspartic residues. 
As a consequence the acronym caspase was coined [12]. The intracellular activation of 
caspases causes specific proteolysis in a specific set of proteins that translates into the 
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cell apoptotic phenotype [13]. The mechanisms that lead to caspase activation have 
been classified into two pathways, the intrinsic and the extrinsic pathway. The extrinsic 
pathway is initiated in membrane receptors, Fas or TNF-R1 for instance, named death 
receptors (DR). Upon binding of their specific ligands, these receptors transduce their 
death signal by means of a caspase, mainly caspase 8 [14]. Therefore, the 
pharmacological inhibition of Caspase 8 implies the blockage of the death signal and 
cells are able to survive facing killer ligands like Fas-L or TNF. The intrinsic pathway is 
defined on the basis of mitochondrial implication. Mitochondria seem to act as a cell 
damage sensor that releases a set of proteins, kept in their intermembrane space, upon 
stressing stimuli. Cytochrome c is one of such proteins and acts by promoting the 
apoptosome assembly and the specific activation of caspase 9 [15]. In this context, the 
pharmacological inhibition of caspases blocks most of the characteristic features of 
apoptosis, but does not avoid cell death [9]. These mitochondrial events are regulated by 
the Bcl-2 family of proteins [16]. These proteins contain homology domains that allow 
reciprocal interactions and specific differences of affinity can be found among them. 
Some members are Bcl-2 agonists and act by preventing apoptosis (Bcl-XL, Bcl-w, Mcl-
1, etc.). The others (Bax, Bak, Bid, etc.) behave as antagonists and promote it. Bcl-2 and 
Bcl-XL are able to inhibit the translocation of cytochrome c to the cytoplasm. As a 
consequence, their overexpression in a cell implies an increased resistance to stimuli 
activating the intrinsic pathway. 
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The induction of apoptosis by means of the pharmacological inhibition of CDK is 
the focus of our research interests. Little is known about the molecular events that take 
place and connect cell detection of CDK dysfunction and apoptosis. In order to 
investigate these mechanisms, we decided to use Olomoucine and Roscovitine, two 
CDK inhibitory drugs. As a cell model, we chose SH-SY5Y, a cell line derived from a 
human neuroblastoma. One reason was our previous experience in characterizing the 
apoptotic phenotype and the molecular mechanisms triggered by STS in these cells 
[9,17,18]. Another reason was their remarkable capability to differentiate in cell culture 
conditions [9,19]. In these cells, Olomoucine and Roscovitine behaved as effective 
inductors of apoptosis. In order to elucidate the biochemical pathways involved, we 
examined the effects of Bcl-2 and Bcl-XL overexpression and were null. In addition, we 
tested caspase inhibition and the blockage of new protein expression. Either action 
reduced apoptosis and displayed synergism in doing so. Finally, the induction of 
differentiation in the cell cultures minimized the ratios of cell death and apoptosis. The 
implications of these results envisaging cell cycle phases, apoptosis and cancer therapy 
will be discussed further. 
 
Materials and methods 
Antibodies and chemical reagents 
AntiBcl-2 (clone 124) monoclonal antibody was purchased from DAKO (Glostrup, 
Denmark). AntiBcl-XL (Catalog # B22630) monoclonal antibody was acquired from 
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Transduction Laboratories (Lexington, KY, USA). AntiRb (clone G3-245) was provided 
by BD Biosciences (Madrid, Spain). AntiβActin (clone AC-15) and secondary peroxidase 
conjugated antibodies were supplied by Sigma (St. Louis, MO, USA). Olomoucine, Iso-
Olomoucine, Roscovitine, PD98059 and Geneticin (G418) were purchased from 
Calbiochem (San Diego, CA, USA). UO126 was purchased from Tocris (Bristol, UK). 
zVADfmk (Benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone) and AcDEVDafc (Acetyl-
Asp-Glu-Val-Asp-7-amino-4-trifluoromethylcoumarin) were obtained from Enzyme 
Systems Products (Livermore, CA, USA). zVADfmk (N-1510) is presently being obtained 
from Bachem (Bubendorf, Switzerland). zVADfmk from Enzyme Systems Products was 
used at a concentration 50µM. zVADfmk from Bachem requires a concentration 100µM 
to yield equivalent results. Fetal calf serum was supplied by Life Technologies/Gibco 
BRL (Barcelona, Spain). CellTiter 96® and Cytotox 96® kits were provided by Promega 
(Madison, WI, USA). TUNEL reactions were performed with the In situ Cell Death 
Detection kit, Fluorescein, from Roche (Barcelona, Spain). Culture media, STS, 
bisBenzimide (Hoechst 33342), propidium iodide, CHX and DAct were purchased from 
Sigma (St. Louis, MO, USA). Unless otherwise stated, the non-listed reagents were also 
from Sigma. 
 
Cell lines, specific culture conditions and drug treatments 
SH-SY5Y cells were grown as reported before [9,17]. SH-SY5Y populations 
transfected with the pcDNA3/Bcl-2, pcDNA3/Bcl-XL and empty pcDNA3 vectors were 
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obtained and characterized in previous research projects [9]. We have observed a 
reduced proliferation in Bcl-2 overexpressing cells, this implied a growing advantage for 
Bcl-2 non-expressing cells. In order to keep overexpression in most cells, G-418 was 
permanently present in cultures unless the experiment was terminal. In addition, Bcl-2 
levels were routinely checked by Western Blot. A similar strategy was applied to Bcl-XL 
overexpressing and pcDNA3/empty control populations. Along our experiments, cell 
cultures were periodically checked for mycoplasm contamination and were repeatedly 
negative by PCR assays. To induce differentiation in SH-SY5Y cells, we followed an 
established procedure [19]. In brief, cells were cultured on collagen coated plates and 
10µM RA (all-trans-Retinoic Acid) was added for five days. RA was purchased from 
Tocris (Bristol, UK). Culture dishes and other plastic disposable tools were supplied by 
Corning (Corning, NY, USA), Sarstedt  (Newton, NC, USA), Bibby Sterilin (Staffordshire, 
UK) and Becton Dickinson (Franklin Lakes, NJ, USA). Olomoucine and Iso-Olomoucine 
were dissolved in DMSO at a concentration 50mM. Roscovitine and zVADfmk were 
prepared with DMSO at a concentration 20mM. Finally, STS was also adjusted with 
DMSO to 1mM. From these working stock solutions, drugs were added to complete 
media. Then serial dilutions were performed in order to obtain the final concentrations 
reported in the text and figures. The resulting DMSO concentration never surpassed 1% 
in the medium. At this concentration we have determined DMSO does not influence SH-
SY5Y cell viability, differentiation or neurite outgrowth. CHX and DAct were soluble in 
culture media and adjusted to the final concentrations reported also in text and figures. 
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Cell viability and cell death determinations 
CellTiter 96® kit provides the MTS reagent, 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxy methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt. MTS is a water-
soluble tetrazolium salt, that permeates cell membranes and is chemically reduced to a 
colored formazan salt inside metabolically competent cells. This fact allows the 
determination of viability in cell cultures. MTS derived formazan salt is characterized by 
being water-soluble, thus circumventing cell lysis or DMSO dissolving steps required in 
the similar MTT procedure [17]. The assay is devised to be applied to multi-well plates, 
thus easing the performance of many independent determinations and further statistical 
analysis. We plated 40.000 SH-SY5Y cells/well in 96 multi-well plates (M96), routinely. 
Color changes were quantified by means of an ELISA plate reader after 24 hours of drug 
treatment. Final values were the result of subtracting 620nm from 490nm lectures. 
Lectures proved to be linear following 3-6 hours of incubation in MTS. Each experimental 
condition was systematically tested in several wells and each experiment repeated 
several times, as stated in the figure legends. Cell viability ratios were obtained by 
referring values from treated to those of untreated, control cultures. 
Cytotox 96® kit provides the reagents and standards to determine lactate 
deshydrogenase activity (LDH) in culture media or cell lysates. LDH enzyme is released 
from cells only upon membrane rupture, as a consequence its measurement quantifies 
death ratios in cell cultures. The assay is also devised to be performed in multi-well 
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plates. In the LDH assays, we plated M96 with 30.000 SH-SY5Y cells/well. Following 48 
hours of drug treatment, LDH release was determined according to the kit instructions. In 
apoptosis, the LDH release is a later event than the decrease of MTS reduction. As a 
consequence, only at 48 hours of drug treatment LDH determinations were consistent 
with MTS ones, which were performed at 24 hours. The increase in LDH was detected 
as a change in color, that was quantifiable by an ELISA plate reader. Final values were 
also the result of subtracting 620nm from 490nm lectures. Each experimental condition 
was systematically tested in several wells and each experiment repeated several times, 
as stated in the figure legends. Cell death ratios were obtained by referring the LDH 
values in the medium of a treated culture to the total LDH content of an equally treated 
control culture. The total LDH content is the result of cell lysis by addition of Triton X-100 
to the culture medium, at a final concentration of 0.9%. The LDH value of complete 
medium and complete medium plus 0.9% Triton X-100 were subtracted from the 
corresponding values. The cell death percentage found in untreated cultures was 
averaged and subtracted from the final death ratios. 
 
Apoptosis assessment 
 We have used five different criteria to asses apoptosis in cell cultures. First, 
nuclear morphology as evidenced by direct 0.05 µg/ml bisBenzimide (Hoechst 33342) 
staining and fluorescence microscopy. Frequently, bisBenzimide/propidium iodide 
double staining was performed. In this case, propidium iodide was added at a final 
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concentration of  25µg/ml. Second, the large DNA fragments of approximately 50 kbp 
(kilobase pairs). This DNA fragmentation was detected by means of a reported 
procedure [20]. However, we used a contour homogeneous electric field (CHEF) system 
(BioRad, Hercules, CA, USA) to perform the agarose gel electrophoresis of the DNA 
samples. The running conditions were 15 hours, at 6 V/cm, initial switching time of 50 
seconds and final switching time of  90 seconds. Third, the internucleosomal DNA 
fragmentation. The ladder pattern of DNA degradation was easily detected by means of 
an standard electrophoresis in 1.5% agarose gels. Fourth, the surge and increase of 
effector caspase activity. We employed a procedure based on reading the fluorescence 
released from the AcDEVDafc synthetic substrate after its direct addition to the culture 
medium, detergent cell lysis and incubation at 37°C. This method allows measurements 
in a M96 format and has been validated in our previous works [9,18]. As a minor 
improvement, Nonidet P-40 detergent has been reduced to 1.6% in the 2X lysis buffer. 
Finally, TUNEL (Terminal deoxynucleotidyl transferase-mediated dUTP Nick End-
Labelling) assays were performed according to the kit instruction manual. Flow 
cytometry readings were obtained by means of an EPICS XL unit from Coulter 
Científica, SA (Madrid, Spain). 
 
Cell cycle analysis  
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Cell cultures were kept on ice and incubated for 15 minutes in 25µg/ml propidium 
iodide, 10µg/ml RNase A and 0,1% Triton X-100. Then, cell suspensions were subjected 
to analysis in the flow cytometer referred before.  
 
Protein extractions and Western Blotting 
To study cytochrome c release from mitochondria, a 0.05% digitonin cytosolic 
extraction was performed according to a reported procedure [21]. The remaining mixture 
of cell constituents (nuclei, mitochondria and other organelles) was extracted as will be 
next described for whole cells. To obtain whole cell extracts, cells were washed with 
phosphate buffered saline (PBS), lysed in a lysis-buffer containing 100 mM Tris/ClH pH 
6.8, 2% SDS, 1 mM EDTA, 1 mM PMSF, 2 µg/ml Aprotinin, 1 µg/ml Leupeptin and 1 
µg/ml Pepstatin, sonicated, and boiled for 5 min. Following a centrifugation at 12000 g 
for 15 minutes, the protein concentration was determined in the supernatants by means 
of the DC Protein Assay from BioRad. These supernatants were subjected to 
electrophoresis in SDS 7-12% polyacrylamide gels. Based on the protein assay, equal 
amounts of protein were loaded per lane. Then, proteins were transferred to PVDF 
membranes (Amersham, Buckinghamshire, UK) by means of a MINI trans-blot module 
from BioRad. Membranes were reacted with the primary antibodies described above. 
Immunoblots were finally developed with the appropriate peroxidase labeled secondary 
antibody and either the SuperSignal West Pico or the SuperSignal West Dura 
reagents from Pierce (Rockford, IL, USA). 
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 Results 
Characterization of the cell death process induced by Olomoucine and Roscovitine in 
SH-SY5Y cells  
In order to characterize the lethal effects of Olomoucine and Roscovitine on the 
SH-SY5Y cell line, cells were cultured on M96 and subjected to serial dilutions of these 
drugs. After 24 hours of treatment, cell viability was determined by measuring the ability 
to reduce MTS (Fig. 1A). Olomoucine and Roscovitine induced cell death in a 
concentration-dependent manner. The drug concentration lethal for 50% of the cell 
population (LC50) was 127,5µM and 25µM, respectively. This was consistent with the "in 
vitro" reports about Roscovitine being a more potent CDK inhibitor than Olomoucine 
[3,4]. Concentrations had to be raised to 200µM Olomoucine or 50µM Roscovitine to kill 
most of the cell population after one day of treatment. Therefore, these higher 
concentrations have become the most frequently employed in our studies. On the other 
hand, Iso-Olomoucine is an isomer of Olomoucine that causes “in vitro” CDK inhibition at 
concentrations far greater than Olomoucine. As it is shown in Fig. 1A, Iso-Olomoucine 
did not cause cell death in the same range of Olomoucine concentrations. As a 
consequence, Iso-Olomoucine has become the most appropriate negative control in our 
experiments.  
As we have commented before, cell viability measurements were based on 
determinations of the cell ability to reduce MTS. Since cell reduction potential can 
decrease by other contingencies not related to cell death, all along our experiments we 
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decided to confirm our MTS data by an independent procedure. The chosen procedure 
was the quantification of the LDH activity released into the culture medium (Fig. 1B). 
This parameter indicates cell membrane rupture and, unequivocally, cell death. Though 
it is also adapted to M96 assays like the MTS method, there is a difference to be noted 
between both procedures. In the MTS procedure, the values from treated cultures can 
be only referred to those of control untreated ones in order to obtain the percentage of 
cell viability. In the LDH procedure, the values of LDH released in the treated cultures 
can be referred to the total LDH content of analogously treated cultures, where total LDH 
has been released by means of cell lysis. This limits the number of determinations to be 
performed per plate and reduces the feasibility to study the broad range of 
concentrations attainable with the MTS procedure (compare Fig. 1A and 1B, for 
example). However, LDH method allows the direct calculation of cell death percentages. 
A parameter that is complementary to the cell viability one obtained with the MTS 
procedure. Along our experiments, LDH and MTS procedures yielded complementary 
values in a reproducible and consistent manner. 
Once we had standardized the concentration and time parameters for cell death 
induction, we proceeded to characterize the type of cell death triggered by Olomoucine 
and Roscovitine in SH-SY5Y cells. First, we characterized the nuclear morphology of 
cells by means of chromatin staining with bisBenzimide and fluorescence microscopy. 
As shown in Fig. 2A, Olomoucine and Roscovitine generated the reduced size and 
condensed nuclei, progressively more fragmented, typical of apoptosis. These images 
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were not found in cultures of SH-SY5Y cells treated with Iso-Olomoucine. Then, we 
analyzed the DNA of Olomoucine, Roscovitine and Iso-Olomoucine treated cells in 
agarose gel electrophoresis under a continuos or a contour-clamped homogeneous 
electric field (CHEF). As expected, Olomoucine and Roscovitine generated the 
internucleosomal DNA degradation and the 50 kbp fragments characteristic of apoptosis 
(Fig. 2B). In order to assess the mitochondrial involvement in this apoptotic process, we 
characterized the cytoplasmic translocation of cytochrome c. After nine hours of 
treatment, cells treated with Olomoucine (Fig. 2C) and Roscovitine (not shown) but not 
Iso-Olomoucine displayed cytochrome c in a cytosolic fraction. The subsequent 
activation of effector caspases was tested by evidencing the specific proteolysis of 
several substrates like poly-ADPribose polymerase (PARP), Fodrin and Lamin B1 in 
Western Blots (not shown). Alternatively, we followed a more quantitative approach by 
determining the activation kinetics of effector caspases 3 and 7. The surge and extent of 
DEVD cleaving activity (DEVDase activity) was measured by means of the fluorescence 
released, upon cleavage, from a synthetic substrate (AcDEVDafc). As shown in Fig. 2D, 
a linear increase in DEVDase activity was found up to 9 hours of drug treatment. 
Olomoucine and Roscovitine kinetics did not differ significantly. However, as expected, 
Iso-Olomoucine kept DEVDase activity at basal levels. In conclusion, all the apoptotic 
features, we had so far checked, were positive. Olomoucine and Roscovitine caused cell 
death by inducing apoptosis in SH-SY5Y cells. 
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MTS and LDH procedures are characterized to quantify all types of cell death and 
not only the apoptotic type. The characterization of apoptosis we have just described is 
basically qualitative. Therefore, a matter of concern was if a significant amount of cells 
were undergoing a non-apoptotic type of cell death. As we have mentioned before, we 
have routinely performed bisBenzimide/propidium iodide double staining and propidium 
iodide had never evidenced a significant population of dead cells without apoptotic 
features. In order to definitively discard this issue, we quantified apoptosis by counting 
individual cells by flow cytometry. The TUNEL procedure was chosen to label the 
apoptotic cells. As shown in Fig. 2E, barely all cells became TUNEL positive after 48 
hours of treatment. In other words, they had undergone apoptotic cell death. 
 
Effects of Bcl-2 and Bcl-XL overexpression on Olomoucine and Roscovitine induced 
apoptosis 
 As we have commented before, Bcl-2 and Bcl-XL overexpression is a very 
effective resource to prevent apoptosis in many experimental paradigms, particularly, in 
those characterized by following an intrinsic or mitochondrial pathway. Therefore, we 
were interested to know if any of these proteins could afford some protection to SH-
SY5Y cells challenged with Olomoucine or Roscovitine. SH-SY5Y populations 
overexpressing either Bcl-2 or Bcl-XL protein were available from our previous studies. 
Both proteins conferred resistance to SH-SY5Y facing STS, being Bcl-XL 
overexpression far more protective than Bcl-2 one [9]. Along the following experiments, 
 17
the protection from STS treatments was routinely tested as a control of Bcl-2 or Bcl-XL 
overfunction. 
 The viability profiles of SH-SY5Y pcDNA3/Bcl-2 and pcDNA3/empty cell 
populations were determined by the MTS procedure after 24 hours of treatment with 
either Olomoucine or Roscovitine (Fig. 3A). No difference was observed between both 
populations. Cell death was also assessed by the LDH procedure and the null protective 
effect of Bcl-2 was also confirmed (Fig. 3B). Bcl-2 overexpressing cells continued to die 
displaying an apoptotic phenotype as revealed by bisBenzimide (not shown) and the 
ladder pattern of DNA degradation (Fig. 3C). Bcl-2 is a protein constitutively expressed 
by SH-SY5Y cells, however the Bcl-2 content resulting from overexpression was neatly 
greater (Fig. 3D). As shown also in this figure, Bcl-2 overexpression did not change the 
Bcl-XL content, which remained undetectable in our Western Blots. 
 Analogously, we determined the viability of SH-SY5Y pcDNA3/Bcl-XL cells 
subjected to Olomoucine or Roscovitine treatments (Fig. 4A). As shown in the figure, 
Bcl-XL overexpression did not protect from these drugs, either. The LDH release 
determinations confirmed this assertion (Fig. 4B). SH-SY5Y pcDNA3/Bcl-XL cells were 
dying by apoptosis as evidenced by the internucleosomal DNA degradation (Fig. 4C). 
Note the first lane of this image, where no ladder is observed in cells that have been 
treated with STS. As stated before, this is a control of an excess of Bcl-XL function in 
these cells [9]. On the other hand, Bcl-XL overexpression did not change the cell content 
of Bcl-2 (Fig. 4D). In summary, neither Bcl-2 nor Bcl-XL overfunction was able to modify 
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the death ratios caused by Olomoucine and Roscovitine treatments. A Bcl-2 or Bcl-XL 
regulated pathway to initiate apoptosis, in other words a conventional intrinsic pathway, 
seemed not to be activated by these drugs. 
 
Effects of zVADfmk on SH-SY5Y cells facing Olomoucine and Roscovitine 
 It is broadly accepted that, in the extrinsic pathway, the signal from the death 
receptors is driven through caspase activation. As a consequence, the pharmacological 
inhibition of caspases translates into cell survival in these models. Conversely, in the 
intrinsic pathway, caspase inhibition translates into blockage of the apoptotic features 
but the ratios of cell death remain unchanged. These facts prompted us to study the 
effect of caspase inhibition in cells treated with Olomoucine and Roscovitine. We chose 
zVADfmk by its broad spectrum of caspase inhibition. The addition of 50µM zVADfmk to 
SH-SY5Y cells challenged with Olomoucine resulted in an increase of cell viability (Fig. 
5A) and a corresponding decrease in the cell death ratios (Fig. 5B). Similar results were 
obtained if Roscovitine was used instead of Olomoucine (Fig. 5A and 5B). The protection 
afforded by zVADfmk was partial, since many cells continued to die. Dying cells did not 
show the typical features of apoptosis. For instance, bisBenzimide/propidium iodide 
double staining showed no nuclear fragmentation in the dead cells (not shown). 
Consistently, no apoptotic DNA ladder was seen despite cell death was taking place 
(Fig. 5C). In summary, zVADfmk was capable of blocking the apoptotic phenotype in all 
cells but prevented cell death in only a subpopulation.  
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 We observed that Olomoucine and Roscovitine were very stable in culturing 
conditions, however zVADfmk experienced an important decay after 24 hours in these 
conditions. By carefully refreshing zVADfmk after 24 hours of culture, we found its 
protective effect could be maintained up to 48 hours of Olomoucine and Roscovitine 
treatment (Fig. 5B). This suggested that the aforementioned cell subpopulation could 
survive in the presence of either Olomoucine or Roscovitine, as far as zVADfmk was 
active and caspases were inhibited. This behavior is characteristic of the apoptotic 
models that follow an extrinsic pathway. Taken together with the previous Bcl-2 and Bcl-
XL results, all the data were pointing to a type I extrinsic pathway or, alternatively, to a 
caspase initiating event in the apoptotic process of this cell subpopulation. 
 In a few experiments Olomoucine concentration was raised to 800µM, 
interestingly zVADfmk maintained the percentage of cell viability at 56,96 ± 0,91 in this 
condition. Note that this viability value did not differ significantly from that observed at 
200µM. This indicated that greater concentrations of Olomoucine did not trigger any 
additional, new mechanism, of cell death or if Olomoucine did, it was also blocked by 
zVADfmk. 
 
Effect of CHX and DAct on SH-SY5Y cells treated with Olomoucine or Roscovitine  
 In the characterization of apoptosis models, a frequently asked question has 
been the requirement of new protein synthesis for the process to be accomplished. To 
answer this question, CHX and DAct have been generally used. In our experiments, we 
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employed these reagents at concentrations far above those described to inhibit 
macromolecular synthesis. Initially, we tested the direct toxicity of these concentrations 
on SH-SY5Y cells (Fig. 6A). After 48 hours of treatment, neither CHX nor DAct caused 
significant amounts of LDH release. The cell death ratios were 10,3 ± 2,1 for CHX and 
20,2 ± 1,6 for DAct. The lower toxicity of CHX justified its preferential use in further 
experiments. Moreover, these concentrations of CHX were not able to activate effector 
caspases in SH-SY5Y cells (See Fig. 6D and 6E). In conclusion, up to 48 hours of 
treatment, CHX was not efficiently inducing apoptosis in the SH-SY5Y cell line. 
 The effect of CHX and DAct on cultures of SH-SY5Y cells treated with either 
Olomoucine or Roscovitine was then assayed. As shown in Figure 6C, both compounds 
performed very well at preventing cell death. The ratios of cell protection surpassed 
those afforded by zVADfmk alone. The results obtained by the MTS procedure were also 
confirmed by the LDH method (Fig. 6B). Next we wondered about a possible synergism 
between macromolecular synthesis and caspase inhibition. As displayed in Figure 6B 
and 6C, this synergism was found. In conclusion, three SH-SY5Y cell subpopulations 
seemed to exist in our cultures. A population of cells protected by CHX but not by 
zVADfmk. An overlapping population protected by both compounds and, finally, a small 
population protected only by zVADfmk (this is schematized in Fig. 9). In order to 
demonstrate that a subpopulation was eluding CHX protection, DEVDase activation 
kinetics was determined in SH-SY5Y cell cultures. As expected, CHX was only partially 
inhibiting DEVDase activity in SH-SY5Y cells treated with 200µM Olomoucine (Fig. 6D) 
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or 50µM Roscovitine (Fig. 6E). This coincided with the apoptotic phenotype observed in 
the scarce cells not protected by CHX (bisBenzimide images, not shown). 
 On the other hand we explored the possible effects of protein synthesis inhibition 
on cell cycle regulation. We explored CDK activity by analyzing the state of 
phosphorylation of a known substrate, the Rb protein. As shown in Fig. 6F, the reduction 
in Rb phosphorylation was already detectable after 24 hours of treatment with CHX. The 
implications of this result will be discussed further. 
 
Olomoucine, Roscovitine and cell differentiation in SH-SY5Y cells 
 Another interesting aspect concerning the mode of action of Olomoucine and 
Roscovitine is their putative ability to induce the differentiation of SH-SY5Y cells. We 
have tested low and high doses, short and long times of incubation, and looked for a 
perceptible neurite outgrowth. The results were repeatedly negative, particularly if 
compared with the prominent neuritogenesis caused by STS [9] or RA differentiating 
treatments (Fig. 7A). 
 Cell differentiation is a physiological process that implies a downregulation of 
CDK function. As a consequence, we thought of studying the effect of cell differentiation 
on cell sensitivity to Olomoucine and Roscovitine. SH-SY5Y cells were seeded on 
collagen coated plates and treated with 10µM RA for five days. The result was a cell 
population displaying a differentiated phenotype (Fig. 7A) and mostly arrested in G0/G1 
phase of the cell cycle (Fig. 7B). The CDK inhibition associated with differentiation was 
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checked by analyzing the state of phosphorylation of Rb protein. As expected, Rb was 
found to be hypophosphorylated in the differentiated cells (Fig. 7C). In conclusion, a cell 
population mostly in a quiescent state was available to test the effects of Olomoucine 
and Roscovitine. Not surprisingly, differentiation implied an increase of cell viability in our 
experimental paradigm as measured by the MTS procedure (Fig. 7D). This result was 
also confirmed by the LDH method (not shown). To better characterize the resistance 
associated with the differentiation process, we performed an experiment in which we 
determined the protection afforded by shorter times of differentiation. As shown in Figure 
7E, there was a strong correlation between cell resistance and the time required for an 
optimal differentiation. At time 0 no protection was found, thus ruling out the putative 
protective effects of 10µM RA and of culturing on collagen coated plates. A minimum of 
24 hours, for differentiation to take place in the absence of Olomoucine or Roscovitine, 
was required to begin to detect some resistance. 
 
Effect of PD98059 and UO126 compounds on proliferating SH-SY5Y cells. 
Extracellular regulated kinases (Erk1 and Erk 2) have been described as targets 
of Olomoucine, Roscovitine and other closely related compounds [4, 22]. In order to 
explore the involvement of these kinases in our model, we proceeded to evaluate the 
lethal effects of PD98059 and UO126 on SH-SY5Y cells. PD98059 and UO126 are not 
chemically related, however they are both cell-permeable and selective inhibitors of MAP 
kinase kinase (MEK). This implies the inhibition of Erk1/Erk2 enzymatic activity. Both 
 23
compounds were employed at final concentrations known to inhibit Erk1/Erk2. We 
observed no reduction in SH-SY5Y cell viability, either measured by the MTS procedure 
at 24 hours (Fig. 8A) or determined by the release of LDH after 48 hours of treatment 
(Fig. 8B). Consistently, no increase in effector caspase activity was found up to 9 hours 
of treatment  (Fig. 8C). In these experiments, STS was used as a positive control to 
induce cell death by apoptosis. Our PD98059 and UO126 compounds proved to be 
active when periodically checked in standardized measurements of Erk1/Erk2 activation 
in response to neurotrophins [23]. In conclusion, a putative inhibition of Erk1/Erk2 by 
Olomoucine and Roscovitine was ruled out as the cause of apoptosis in SH-SY5Y cells. 
 
Discussion 
 In this work we have characterized some basic aspects of the cell death process 
triggered by two CDK inhibitory drugs, Olomoucine and Roscovitine, in a human cell line 
derived from neuroblastoma, SH-SY5Y. We have determined the cell death process to 
be dose-dependent and the range of concentrations that caused it. Care was taken not 
to rely on only one procedure to quantify cell death. Two different methods detecting 
independent cell death phenomena were used. In fact, a non-quantifiable third one, cell 
detachment and fragmentation, was routinely assessed and was always congruent with 
the numerical data. We have identified apoptosis as the type of cell death induced by 
Olomoucine and Roscovitine. In order to gain insight into the mechanisms activated to 
generate apoptosis, we used SH-SY5Y cells overexpressing functional Bcl-2 and Bcl-XL 
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proteins. Surprisingly, no protective effect was found. This result is in agreement with the 
one reported in HeLa cells overexpressing Bcl-2 and facing Flavopiridol [24]. It has also 
been reported that an increased Bcl-2 content does not afford any resistance to 
Flavopiridol in cells from a chronic B lymphocytic leukemia [25]. However, Bcl-2 
overexpression proved capable of protecting MB-468 breast cancer cells from this drug 
[26]. One report is also found about Roscovitine induced apoptosis being prevented by 
Bcl-2 overexpression in a human leukemia cell line [27]. Finally, Bcl-2 and Bcl-XL 
prevented apoptosis triggered by a new CDK1 specific inhibitor, CGP74514A [28]. We 
have not detected any additional report addressing this specific issue. The drug and cell 
type contingency notwithstanding, we have not found any satisfactory explanation for the 
discrepancies. 
In order to inhibit a broad spectrum of caspases, we used zVADfmk and found it 
was not only able to inhibit the apoptotic phenotype but cell death caused by 
Olomoucine and Roscovitine. The inhibition of cell death was partial and seemed to be 
maintained as long as zVADfmk was not degraded. This indicated a caspase initiating 
event in a specific subpopulation of the cell culture. Moreover, the null protective effect 
of Bcl-2 and Bcl-XL suggested this subpopulation was behaving like cells following a 
type I extrinsic pathway. Usually, this means the involvement of Fas type death 
receptors (DR). However, the initiation of a caspase cascade in the endoplasmic 
reticulum or Golgi apparatus can mimic a type I pathway [29]. Moreover, the cascade 
could be initiated in the nucleus, where CDK exert their function. Interestingly, caspase 9 
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has been described to be inhibited by forming a complex with survivin in mitotic cells. A 
complex which integrity is dependent upon CDK1 mediated phosphorylation of survivin 
[30]. Therefore, pharmacological inhibition of CDK1 should imply caspase 9 release and 
a type I apoptosis in a subpopulation of mitotic cells. Before exploring these alternative 
pathways, in our future experiments we will try to discard first the involvement of DR in 
the apoptotic process induced by Olomoucine and Roscovitine. 
Protein synthesis inhibition by means of CHX and DAct reduced Olomoucine 
and Roscovitine induced apoptosis. A similar result has been reported in a lung 
carcinoma cell line treated with Flavopiridol [31]. The effect of CHX and DAct on 
apoptosis was an important point in the early times of apoptosis studies, that has not 
attracted much attention afterwards. In many models, both agents prevented apoptosis 
from occurring. In these models, the synthesis of new proteins was hypothesized to be 
required for apoptosis to take place. In other models, both agents triggered cell death by 
themselves and defined the release type of apoptosis [32]. In the release models, the 
existence of a short living, apoptosis blocking protein, that is continuously synthesized, 
was hypothesized. In both types of models, there has been a very limited success in 
identifying the hypothesized gene products. The molecular machinery of apoptosis has 
revealed to be constitutive and not to require new protein synthesis to be activated 
[10,14,15]. An increase of reduced glutathione, caused by CHX, was proposed to 
prevent oxidative stress and to be the explanation of the CHX antiapoptotic properties 
[33]. We propose an alternative hypothesis, CHX and DAct are going to block the 
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synthesis of cyclins [34,35], then inhibit CDK and stop the cell cycle. If cells are able to 
withstand this insult, as SH-SY5Y cells seem to, they will no longer offer a target for CDK 
inhibitory drugs. Indeed, we have evidence that CHX and DAct markedly stop cell growth 
in SH-SY5Y cells (estimations from the total LDH content). This is consistent with the Rb 
hypophosphorylation we have found in CHX-treated SH-SY5Y cells (Fig. 6F).  Moreover, 
our hypothesis is reinforced by the study of thymocytes [36,37] and neuronal cell [38,39] 
models in which CDK activity is required for apoptosis to be accomplished. In these 
experimental paradigms, Olomoucine and Roscovitine have been useful tools to block 
apoptosis and to confirm the CDK involvement. Based on our hypothesis, CHX should 
prevent apoptosis in these paradigms. This seems to be the case either in thymocytes 
[40,41] or in the neuronal models [42, 43]. 
Another important point is the synergy observed between protein synthesis 
inhibition and zVADfmk treatments. Based on this combination of treatments, we can 
distinguish three different subpopulations in a culture of SH-SY5Y cells. Each 
subpopulation following a specific pathway towards cell death (schematized in Fig. 9). In 
two pathways there is an apical event blocked by CHX. In the third one the apical event 
seems to be the initiation of a caspase cascade. In the CHX protected cells, some are 
also protected by caspase inhibition while the other are not. In conclusion, Olomoucine 
and Roscovitine seem to trigger different molecular mechanisms that lead to apoptosis in 
SH-SY5Y cells. We believe the cell cycle is the cause of this heterogeneity. We favor the 
hypothesis that the referred subpopulations reflect the phase in which the cell was 
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cycling at the moment of drug treatment. Fig. 9 is a working hypothesis that we expect to 
test in the future. We will study the apoptotic process triggered by Olomoucine and 
Roscovitine in synchronized populations of SH-SY5Y. Following a similar approach, 
Flavopiridol has demonstrated to increase the induction of apoptosis in transformed cells 
synchronized in S phase [44].  
The specificity of drugs is a general matter of concern in pharmacological 
studies. Presently, research efforts are being devoted to characterize as much "in vivo" 
targets of these CDK inhibitory drugs as possible. These new targets could help to 
explain the biological actions and the putative lack of specificity of these compounds 
[45]. However, in our experiments elevated Olomoucine concentrations seem not to 
engage additional mechanisms leading to cell death. In addition, we have discarded the 
involvement of Erk-1/Erk-2 inhibition as the mechanism causing apoptosis. We do not 
know if Olomoucine and Roscovitine can inhibit other CDK subtypes in our cells, for 
example CDK8 and CDK9. These CDK subtypes are mainly involved in transcriptional 
activation. Consistently, Roscovitine has demonstrated the ability to inhibit transcription 
in herpesvirus [46] and human cells [47]. Therefore, it could be proposed that 
Olomoucine and Roscovitine could be apoptotic agents through their inhibition of 
transcription. Our results do not support this hypothesis. Let us remember that very high 
concentrations of CHX or DAct do not induce apoptosis in SH-SY5Y cells (Fig. 6A). In 
other words, SH-SY5Y cells do not display a release model of apoptosis. Another 
advantage of the SH-SY5Y cell line is the capability to be differentiated in cell culture 
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conditions. Differentiation implies cell quiescence and a physiological downregulation of 
CDK activity. If apoptosis is the result of CDK inhibition by Olomoucine and Roscovitine, 
cell resistance would be expected in differentiated SH-SY5Y cells. Though partial, as 
partial is probably the extent of differentiation in the culture, the resistance has been 
evidenced in our work. Obviously, we can not exclude other differentiation-related events 
capable of explaining the resistance to both compounds. However, taken together our 
results, we believe the role of CDK1 and CDK2 as targets for Olomoucine and 
Roscovitine in apoptosis induction has been reinforced.  
In the introduction section, we commented the putative cytostatic, differentiation-
inducing and cytocidal properties of Olomoucine and Roscovitine to treat cancer. No 
differentiation-inducing properties have been observed in SH-SY5Y cells, however both 
compounds have induced apoptosis efficiently. Apoptosis induction was found in 
growing cells and markedly neutralized in quiescent, differentiated cells. As a 
consequence, a preference for proliferating and undifferentiated tumor cells can be 
inferred. This is a common property found in most anticancer drugs. However, 
Olomoucine and Roscovitine were able to circumvent the antiapoptotic effects of Bcl-2 
and Bcl-XL proteins, two proven oncogenic factors that cause resistance to 
chemotherapy. In conclusion, Olomoucine, Roscovitine and, probably, other related 
compounds display a promising profile as anticancer drugs. Particularly, as we have just 
reported, in the treatment of neuroblastoma. 
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FIG. 1. Cell death induced by Olomoucine and Roscovitine was concentration-
dependent. A) SH-SY5Y cells in culture were treated for 24 hours with Roscovitine (❑) 
in a range of concentrations 6.7 to 50µM. Cells were also treated with Olomoucine (■) 
and Iso-Olomoucine (●) in a range of concentrations 26.7 to 200µM. Cell viability was 
quantified by means of the MTS reduction assay. The survival percentage was obtained 
by referring the obtained values to those of control untreated cells. Every point is the 
mean ± SEM (Standard Error of Media) of at least five independent experiments with six 
independent determinations per experiment. B) SH-SY5Y cells were treated for 48 hours 
with either Olomoucine or Roscovitine at the concentrations specified. Cell death was 
measured by determining the LDH released to the culture medium. The percentage was 
calculated by referring this value to that of the total LDH content of a control culture 
subjected to the same treatment. In addition, the cell death percentage found in 
untreated cultures was averaged and subtracted from the displayed final death ratios. 
Every bar indicates the mean ± SEM of at least four independent experiments with at 
least three independent measurements per experiment. 
 
FIG. 2. Olomoucine and Roscovitine induced apoptosis in SH-SY5Y cells. A) SH-SY5Y 
cells were treated for 24 hours with 200µM Iso-Olomoucine, 200µM Olomoucine and 
50µM Roscovitine. Following bisBenzimide staining of DNA, cells were photographed 
with an inverted fluorescence microscope. Arrows point to chromatin condensations 
typical of different stages of the apoptotic process. Scale bar = 50µM. B) DNA was 
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extracted from cells untreated (1) or treated for 12 hours with 200µM Olomoucine (2), 
200µM Iso-Olomoucine (3) or 50µM Roscovitine (4). The ladder pattern of DNA 
degradation that characterizes apoptosis was detected in 1.5% agarose gels. The large 
DNA fragmentation that is characteristic of apoptosis was resolved by means of a CHEF 
electrophoresis. Std is a commercial standard of DNA. The position of the 50 kbp band is 
indicated in the figure.  C) SH-SY5Y cells were treated with 200µM Olomoucine and 
200µM Iso-Olomoucine. Then cytosolic extracts were performed at the time periods 
indicated in the figure. These extracts were analyzed by Western Blot to show the 
release of cytochrome c from mitochondria. The identity of the upper band is unknown 
but is an useful control of the amount of protein loaded per lane. D) Time-course of 
effector caspase activation (DEVDase activity measured in arbitrary fluorescence units). 
SH-SY5Y cells were treated with 200µM Olomoucine (■), 200µM Iso-Olomoucine (●) 
and 50µM Roscovitine (❑) for the time periods indicated in the graph and the 
fluorescence released from a AcDEVDafc substrate was determined. Every point is the 
mean ± SEM of two independent experiments with two independent measurements per 
experiment. E) Cells were treated as indicated in the graph, subjected to the TUNEL 
procedure and analyzed by flow cytometry. The percentage of apoptotic cells is indicated 
after 24 (full bars) and 48 hours of treatment (open bars). The bar is the mean ± SEM of 
at least two independent experiments. 
 
FIG. 3. Bcl-2 overexpression did not protect cells from Olomoucine or Roscovitine 
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challenge. A) SH-SY5Y pcDNA3/Bcl-2 (❑) and pcDNA3/empty (■) cell populations 
were compared following a 24 hour treatment with either Olomoucine or Roscovitine, as 
indicated in the graphs. Cell survival was assessed by the MTS procedure as in figure 1. 
Every point is the mean ± SEM of three independent experiments with six independent 
measurements per experiment. B) SH-SY5Y pcDNA3/Bcl-2 (open bars) and 
pcDNA3/empty cell populations (full bars) were also treated with Olomoucine and 
Roscovitine for 48 hours. Cell death was determined by the LDH procedure. Every bar is 
the mean ± SEM of two independent experiments with three independent determinations 
per experiment. C) DNA ladders in 1.5% agarose gels. Cells were treated for 12 hours 
with 1µM STS (1), 200µM Iso-Olomoucine (2), 200µM Olomoucine (3) and 50µM 
Roscovitine (4). D) The Bcl-XL and Bcl-2 content of pcDNA3/Bcl-2 and pcDNA3/empty 
cell populations. Western Blots were performed and reacted with antiBcl-XL and antiBcl-
2 antibodies. AntiActin antibody was used to demonstrate equal protein load. 
 
FIG. 4. Bcl-XL overexpression did not protect cells from Olomoucine or Roscovitine 
challenge. A) SH-SY5Y pcDNA3/Bcl-XL (❑) and pcDNA3/empty (■) cell populations 
were compared following a 24 hour treatment with either Olomoucine or Roscovitine, as 
indicated in the graphs. Cell survival was assessed by the MTS procedure as in previous 
figures. Every point is the mean ± SEM of three independent experiments with six 
independent measurements per experiment. B) SH-SY5Y pcDNA3/Bcl-XL (open bars) 
and pcDNA3/empty cell populations (full bars) were also treated with Olomoucine and 
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Roscovitine for 48 hours. Cell death was determined by the LDH procedure. Every bar is 
the mean ± SEM of two independent experiments with three independent determinations 
per experiment. C) DNA ladders in 1.5% agarose gels. Cells were treated for 12 hours 
with 1µM STS (1), 200µM Iso-Olomoucine (2), 200µM Olomoucine (3) and 50µM 
Roscovitine (4). D) The Bcl-XL and Bcl-2 content of pcDNA3/Bcl-XL and pcDNA3/empty 
cell populations. Western Blots were performed and reacted with antiBcl-XL and antiBcl-
2 antibodies. AntiActin antibody was used to demonstrate equal protein load. 
 
FIG. 5. SH-SY5Y cells were partially protected from Olomoucine and Roscovitine 
challenge by zVADfmk. A) SH-SY5Y cells were treated with Olomoucine or Roscovitine 
for 24 hours in the presence (❑) or absence (■) of 50µM zVADfmk in the culture 
medium. Cell survival was assessed by the MTS procedure. Every point is the mean ± 
SEM of five independent experiments with six independent measurements per 
experiment. B) SH-SY5Y cells were treated for 48 hours as indicated in the figure. The 
culture medium contained (open bars) or did not contain (full bars) 50µM zVADfmk. To 
circumvent zVADfmk decay, it was refreshed at 24 hours of treatment. Every bar 
indicates mean ± SEM of at least three independent experiments with at least three 
independent measurements per experiment. C) SH-SY5Y cells were treated for 12 hours 
with 1µM STS (1), 200µM Iso-Olomoucine (2), 200µM Olomoucine (3) and 50µM 
Roscovitine (4). As shown in the picture, some cells were cultured in the presence of 
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50µM zVADfmk. DNA was extracted and internucleosomal DNA degradation observed 
in agarose gels.  
 
FIG. 6. Inhibitors of new protein synthesis prevented apoptosis to a greater extent than 
zVADfmk in SH-SY5Y treated with either Olomoucine or Roscovitine. A) SH-SY5Y cells 
were treated for 48 hours with CHX, DAct and STS at the concentrations reported in the 
graph. LDH release was determined to quantify cell death. As evidenced, the toxicity 
derived from the inhibition of new protein synthesis was low. B) Cells were also 
challenged with 200µM Olomoucine (full bars) and 50µM Roscovitine (open bars), in the 
absence or presence of CHX, zVADfmk or both. Cell death was quantified following the 
LDH procedure. Bar value is the mean ± SEM that results from at least two independent 
experiments with at least 3 independent measurements per experiment. C) Cells treated 
with 200µM Olomoucine (full bars) and  50µM Roscovitine (open bars) were also treated 
with DAct, CHX, and zVADfmk as indicated in the graph. Cell viability was obtained by 
measuring the reduction of MTS. Bar value is the mean ± SEM of three experiments with 
6 independent measurements per experiment. D) Time course of effector caspase 
activation was determined in SH-SY5Y cells treated with 200µM Olomoucine (▲), 
12µg/ml CHX (■) or both (▼). Every point is the mean ± SEM of two independent 
experiments with two independent measurements per experiment. E) Time course of 
effector caspase activation in SH-SY5Y cells challenged with 50µM Roscovitine (▲), 
12µg/ml CHX (■) or both (▼). Every point is the mean ± SEM of two independent 
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experiments with two independent measurements per experiment. DEVDase activity was 
measured in arbitrary fluorescent units. F) CHX induced hypophosphorylation of Rb 
protein. Rb from proliferating (control), 12µg/ml CHX for 24 hours (+CHX) and 10µM RA 
for five days (+RA) treated SH-SY5Y cells was analyzed by Western Blot. 
 
Fig 7. Differentiated SH-SY5Y cells displayed an increased resistance to Olomoucine 
and Roscovitine. A) Phase contrast photographs of control and RA-differentiated SH-
SY5Y cells (+RA). The arrow points to the prominent neurite projections characteristic of 
neuronal differentiation. Scale bar = 100µM. B) Cell cycle profile of control and 
differentiated SH-SY5Y cells. Differentiation implied S phase reduction and cell 
accumulation in G0/G1 phase. The profile is representative of several recorded profiles, 
obtained along the differentiation experiments. C) The state of phosphorylation of Rb 
protein was determined by Western Blot. The hyperphosphorylation characteristic of a 
growing control population decreases in a non-cycling differentiated one (+RA). D) SH-
SY5Y cells differentiated with RA for five days (▲) and proliferating untreated controls 
(▼) were treated for 24 hours with Olomoucine and Roscovitine in the range of 
concentrations shown. Cell viability was quantified by the MTS assay. Every point is the 
mean ± SEM of at least five independent experiments with six independent 
determinations per experiment. E) SH-SY5Y cells were differentiated with RA for the 
days indicated in the graph. Then 200µM Olomoucine (●) or 50µM Roscovitine (▲) 
were added to the culture and cell viability determined after 24 hours. Cell resistance to 
 42
both drugs increased proportionally to the days of RA treatment. Cell viability was 
quantified by the MTS procedure. Every point is the mean ± SEM of six independent 
determinations. 
 
FIG. 8. PD98059 and UO126 did not induce cell death in SH-SY5Y cells. A) Cells were 
treated as indicated in the figure. STS was used as a positive control of cell death. Cell 
viability was measured by the MTS procedure. The mean ± SEM of three independent 
experiments with at least six independent measurements per experiment is shown. B) 
Cells were treated as before and cell death was determined by the LDH procedure. 
Every bar is the mean ± SEM of two independent experiments with at least three 
independent determinations per experiment. C) Time-course of effector caspase 
activation. SH-SY5Y cells were treated with 50µM PD98059 (❍), 15µM UO126 (●) and 
1µM STS (▲) for the time periods indicated. The value of control untreated cells is 
placed at time 0 (■). DEVDase activity was measured in arbitrary fluorescence units. 
Every point is the mean ± SEM of at least five independent determinations. 
 
FIG. 9. Scheme of the putative pathways leading to cell death in SH-SY5Y cells facing 
Olomoucine or Roscovitine treatment. The three pathways are defined on the basis of 
the synergism detected between CHX and zVADfmk (Fig. 6C). Each pathway defines a 
specific subpopulation in the culture of SH-SY5Y cells. We believe a specific cycle phase 
is underlying each subpopulation. This is a working hypothesis. Each pathway is initiated 
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by the pharmacological inhibition of CDK. CDK ? means that the specific CDK number 
(either 1 or 2) is not known. CASPi means an initiating caspase, not an effector one. X is 
the unknown number identifying this specific caspase. 
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